참고문헌
- Fricker SP, Buckley RG. Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. Anticancer Res. 1996. 16: 3755-3760.
- Hua DH, Lou K, Battina SK, Zhao H, Perchellet EM, Wang Y, Perchellet JP. Syntheses, molecular targets and antitumor activities of novel triptycene bisquinones and 1,4-anthracenedione analogs. Anticancer Agents Med Chem. 2006. 6: 303-318. https://doi.org/10.2174/187152006777698141
- Li W, Lam MS, Birkeland A, Riffel A, Montana L, Sullivan ME, Post JM. Cell-based assays for profiling activity and safety properties of cancer drugs. J Pharmacol Toxicol Meth. 2006. 54: 313-319. https://doi.org/10.1016/j.vascn.2006.02.014
- Marshall L. The Cancer Outlook 2000, Datamonitor PLC, London.
- Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Meth. 1997. 208: 151-158. https://doi.org/10.1016/S0022-1759(97)00137-3
- Pauwels B, Korst AE, de Pooter CM, Pattyn GG, Lambrechts HA, Baay MF, Lardon F, Vermorken JB. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol. 2003. 51: 221-226.
- Seo HY, Kim YD, Lee KM, Min AK, Kim MK, Kim HS, Won KC, Park JY, Lee KU, Choi HS, Park KG, Lee IK. Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner. Endocrinology 2008. 149: 3832-3841. https://doi.org/10.1210/en.2008-0015
- Valler MJ, Green D. Diversity screening versus focused screening in drug discovery. Drug Discov Today 2000. 5: 286-293. https://doi.org/10.1016/S1359-6446(00)01517-8
- Weinstein JN, Buolamwini JK. Molecular targets in cancer drug discovery: cell-based profiling. Curr Pharm Des. 2000. 6: 473-483.
-
WHO Fact sheet
${N^{\circ}}$ 297 (2009) http://www.who.int/mediacentre/ factsheets/fs297/en/